Latest Oncology News

Subcutaneous Epcoritamab Demonstrates Early Activity, Favorable Tolerability in CLL

Subcutaneous Epcoritamab Demonstrates Early Activity, Favorable Tolerability in CLL

January 16th 2022

Maggie Tibbitt

Subcutaneous epcoritamab demonstrated early activity and favorable tolerability in patients with relapsed/refractory chronic lymphocytic leukemia and high-risk features.

Intensive Chemotherapy Falls a Few Steps Behind in Leukemia and Lymphoma

Intensive Chemotherapy Falls a Few Steps Behind in Leukemia and Lymphoma

January 15th 2022

Caroline Seymour

Naval Daver, MD, discusses the latest developments in acute lymphoblastic leukemia, chronic lymphocytic leukemia, acute myeloid leukemia, and follicular lymphoma.

Ibrutinib Increases Risk of Select Cardiovascular AEs in Patients With Chronic Lymphocytic Leukemia

Ibrutinib Increases Risk of Select Cardiovascular AEs in Patients With Chronic Lymphocytic Leukemia

January 14th 2022

Chris Ryan

Treatment with ibrutinib in patients with chronic lymphocytic leukemia was linked with increased risk of cardiovascular adverse effects like atrial fibrillation, hospital-diagnosed bleeding, and heart failure, but was not linked with a higher risk of acute myocardial infarction or stroke.

Selecting the Optimal Treatment Approach for Difficult-to-Treat, Relapsed/Refractory Myeloma

Selecting the Optimal Treatment Approach for Difficult-to-Treat, Relapsed/Refractory Myeloma

January 14th 2022

Ryan Scott

Certain patient and disease characteristics must be considered to select the optimal treatment approach for difficult-to-treat patients with relapsed or refractory multiple myeloma.

New, Updated Data Demonstrate Promising Future in Advanced Melanoma

New, Updated Data Demonstrate Promising Future in Advanced Melanoma

January 14th 2022

Jackie Collins

Jeffrey S. Weber, MD, PhD, overviews the successes made in the melanoma setting in the past decade and the challenges to overcome in the future.

Latest Oncology Videos

All Oncology News

Immunotherapy Outcomes in HPV-Associated Head and Neck Cancer Fuel Investigative Efforts

January 14th 2022

Maggie Tibbitt

Robert L. Ferris, MD, PhD, discusses the current standard of care for patients with head and neck cancer, the role of HPV in treatment decisions, and the need to personalize therapy for patients.

Optimized Treatment Starts With Molecular Testing in NSCLC

January 14th 2022

Caroline Seymour

Konstantinos Arnaoutakis, MD, discusses new strategies in the management of ALK-positive non–small cell lung cancer, frontline immunotherapy, targeting EGFR, and biomarkers and targeted therapies in early-stage and advanced disease.

Real-Time Tumor Targeting: Police Officer First to Have New Radiotherapy Technology

January 14th 2022

A 59-year-old police officer with prostate cancer was treated with the Elekta Unity MR-Linac, a breakthrough innovation that simultaneously generates magnetic resonance images and delivers radiation directly to the tumors.

3D Virtual Reality Poised to Offer Superior Patient Education in Oncology

January 14th 2022

Kyle Doherty

Patient education in oncology can often be daunting and complicated for clinicians and patients.

Zanubrutinib Improves PFS in Treatment-Naïve CLL/SLL

January 14th 2022

Caroline Seymour

Zanubrutinib elicited a statistically significant improvement in progression-free survival vs the combination of bendamustine and rituximab in patients with treatment-naïve chronic lymphocytic leukemia and small lymphocytic lymphoma.

Ibrutinib/Rituximab Combo Represents Effective Chemo-Free Option for Elderly Patients with MCL

January 13th 2022

Chris Ryan

The combination of ibrutinib and rituximab produced a high overall response rate and durable survival in elderly patients with mantle cell lymphoma.

Wealth of Newer Treatment Options Span the Scope of Multiple Myeloma and Amyloidosis

January 13th 2022

Jessica Hergert

Tomer Mark, MD, discusses the emerging role of minimal residual disease as a surrogate end point in multiple myeloma, treatment selection for patients with newly diagnosed, early relapsed, and late relapsed disease, and the importance of daratumumab being introduced to the treatment paradigm of amyloidosis.

MB-106 Elicits Durable Responses and Demonstrates Tolerable Safety Profile in DLBCL, MCL, Follicular Lymphoma

January 13th 2022

Maggie Tibbitt

Mazyar Shadman, MD, MPH, discusses the utility of MB-106 for the treatment of patients with relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL) and chronic lymphocytic leukemia.

Basu on Getting Ahead of the Shadow Curve of COVID-19 in Oncology

January 13th 2022

OncLive Staff

Dr Basu discusses the “shadow curve” that could result from disruptions in cancer care during the COVID-19 pandemic and innovative strategies that Cancer Treatment Centers of America are taking to avoid this.

ADXS-503 Plus Pembrolizumab Shows Early Clinical Benefit, Safety in Metastatic NSCLC

January 13th 2022

Kristi Rosa

The addition of ADXS-503 to the treatment of patients with metastatic non–small cell lung cancer who were progressing on pembrolizumab (Keytruda) resulted in encouraging responses and durable disease control, according to findings from the phase 1/2 trial.

Adagrasib With or Without Cetuximab Produces Encouraging Clinical Activity in KRAS G12C–Mutant CRC

January 13th 2022

Maggie Tibbitt

Jared Weiss, MD, sheds light on the exploration of adagrasib as a monotherapy and in combination with cetuximab in patients with KRAS G12C–mutated metastatic colorectal cancer, key findings from the KRYSTAL-1 study, and next steps for research.

Low Country Cancer Care Expands Further in Georgia & Opens New Statesboro Clinic

January 13th 2022

Low Country Cancer Care is pleased to announce the opening of their new cancer center in Statesboro, Ga., located at 1601 Fair Road, Suite 900. This new clinic is the fifth LCCC location, making it easier for patients to have access to the highest quality cancer care close to where they live.

Overcoming Barriers to Clinical Access in Oncology Care Delivery Requires Multilevel Interventions

January 13th 2022

Christopher S. Lathan, MD, MS, MPH

Christopher S. Lathan, MD, MS, MPH, discusses the lack of dissemination and implementation of evidence-based health care delivery innovations focused on addressing disparities in care.

Incorporation of Chemotherapy-Free Regimens Improve Outcomes in Hematologic Malignancies

January 13th 2022

Jessica Hergert

Thomas Kipps, MD, PhD, discussed navigating treatment regimens in CLL and MCL, the success of brentuximab vedotin in Hodgkin lymphoma, choosing between TKIs in CML, and the importance of transfusion independence in MDS.

FDA Grants RMAT/Fast Track Designations to C-CAR039 for Relapsed/Refractory DLBCL

January 12th 2022

Kristi Rosa

The FDA has granted a regenerative medicine advanced therapy designation and a fast track designation to C-CAR039 for use as a potential therapeutic option in patients with relapsed or refractory diffuse large B-cell lymphoma.

See All News